Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Prakash Vishnu1 Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, University of Washington, Seattle, WA, USA

David M Aboulafia1 Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, University of Washington, Seattle, WA, USA;2 Division of Hematology, University of Washington, Seattle, WA, USACorrespondence[email protected]

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Frederick Chen, Vickie McDonald & Adrian Newland. (2021) Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). Expert Opinion on Biological Therapy 21:11, pages 1383-1393.
Read now

Xueqing Dou & Renchi Yang. (2019) Current and emerging treatments for immune thrombocytopenia. Expert Review of Hematology 12:9, pages 723-732.
Read now

Articles from other publishers (1)

A. N. Afanasyeva, V. B. Saparova, D. D. Karal-Ogly, E. I. Mukhametzyanova, D. V. Kurkin, A. V. Kalatanova, I. E. Makarenko, A. L. Khokhlov & I. A. Lugovik. (2022) SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR. Pharmacy & Pharmacology 10:4, pages 354-370.
Crossref

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Citations (3)

Read on this site (2)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date